miR-146a mimic therapy protects against platelet-mediated thrombosis

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Research

Background:

• MicroRNA-146a (miR-146a) expression varies due to genetic factors like rs2431697, linked to cardiovascular events.
• The precise mechanisms connecting miR-146a genotype to thrombotic events are not fully understood.

Purpose of the Study:

• To investigate the functional role of miR-146a deficiency in platelet activation and thrombotic events.
• To elucidate the metabolic pathways affected by miR-146a deficiency in platelets.

Main Methods:

• Comparative analysis of platelets from miR-146a deficient (miR-146a-/-) and wild-type mice.
• Assessment of platelet aggregation under static and flow conditions.
• Metabolomic profiling and gene expression analysis (Cpt1a).
• In vivo thrombosis models and therapeutic intervention with miR-146a mimic.

Main Results:

• miR-146a deficiency led to hyperreactive platelets and increased thrombosis in mice.
• Metabolomics revealed enhanced fatty acid oxidation in miR-146a-/- platelets due to elevated Cpt1a expression.
• Restoring miR-146a in myeloid cells protected against thrombosis in vivo.

Conclusions:

• miR-146a deficiency promotes platelet hyperreactivity and thrombosis via metabolic reprogramming, specifically enhanced fatty acid oxidation.
• Targeting miR-146a levels could be a therapeutic strategy for preventing cardiovascular events associated with thrombosis.